Abstract
Lung cancer continues to be the leading cause of cancer death in Western countries. The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and chemotherapy is the treatment of choice for most patients with metastatic NSCLC. Platinum-based chemotherapy has long been the standard of care for advanced NSCLC. The formation of new blood vessels (angiogenesis) is needed for the growth and invasiveness of primary tumours, and plays an important role in metastatic growth. Vascular endothelial growth factor (VEGF) has emerged as a key potential target for the pharmacological inhibition of tumour angiogenesis. This review discusses current data and the future potential of bevacizumab, a recombinant humanized monoclonal antibody that binds VEGF, in the treatment of NSCLC.
Results from a phase II study showed that the addition of bevacizumab to the first-line chemotherapy with paclitaxel and carboplatin (CP) may increase the overall survival (OS) and the time to progression in advanced NSCLC. Based on these promising results, a randomized phase III trial compared the combination of bevacizumab with CP versus CP alone in the treatment of advanced non-squamous NSCLC. The combination of CP plus bevacizumab led to a statistically significant increase in median OS and progression-free survival (PFS) compared with CP alone, with a response rate (RR) in the CP arm of 15% compared with 35% in the bevacizumab plus CP arm (p < 0.001). More recently, the randomized AVAIL (Avastin in Lung Cancer) study, which evaluated cisplatin with gemcitabine plus bevacizumab in two different dosages versus chemotherapy alone in 1043 patients with recurrent or advanced non-squamous NSCLC, reported a significant increase of PFS, RR and duration of response for both of the bevacizumab-containing arms. Bevacizumab has also been investigated in combination with erlitonib as second-line treatment in two small early phase trials, with interesting results.
Bevacizumab was generally well tolerated in clinical trials; the main treatment-associated adverse events were neutropenia and haemorrhage, especially in the lung, but also at other sites. Several trials that incorporate bevacizumab in combination with new active drugs in NSCLC are ongoing and should further help to define the place of bevacizumab in the therapy of NSCLC.
Similar content being viewed by others
References
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br J Med 1995; 311: 899–909
Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459–65
Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122–30
Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer project. J Clin Oncol 1999; 17: 3522–30
Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210–8
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8
Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285–91
Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase II study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group. J Clin Oncol 2003; 21: 3016–24
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330–53
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6
Ferrara N, Kerbel RS. Angiogenesis as therapeutic target. Nature 2005; 438: 967–74
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76
Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique ‘window’ of opportunity. Cancer Cell 2004; 6: 529–31
Herbst RS, Onn A, Sandler A. Agiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243–56
Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007; 26: 3691–8
Trivella M, Pezzella F, Pastorino U, et al. Microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of individual patients data. Lancet Oncol 2007; 8: 488–99
Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995; 6: 1059–62
Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861–5
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91
Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50
Manegold C, Von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapynaive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract no. LBA7514]. Proc Am Soc Clin Oncol 2007; 25: 388s
Patel JD, Hensing TA, Villafor V, et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): preliminary results [abstract no. 7601]. Proc Am Soc Clin Oncol 2007; 25: 409s
Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC) [abstract no. 17009]. Proc Am Soc Clin Oncol 2006; 24: 667s
Groen HJ, Smit EF, Dingemans A, et al. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract no. 7625]. Proc Am Soc Clin Oncol 2007; 25: 415s
Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study [abstract no. 7535]. Proc Am Soc Clin Oncol 2007; 25: 393s
Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544–55
Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2007; 25: 4743–50
A study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (ATLAS) [ClinicalTrials.gov identifier: NCT00257608]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00257608 [Accessed 2008 Mar 3]
A study of bevacizumab in combination with first-or second-line therapy in subjects with treated brain metastases due to non-squamous NSCLC (PASSPORT) [ClinicalTrials.gov identifier: NCT00312728]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00312728 [Accessed 2008 Mar 3]
A study of bevacizumab plus carboplatin and paclitaxel in subjects with advanced, previously untreated, squamous non-small cell lung cancer (BRIDGE) [ClinicalTrials.gov identifier: NCT00318136]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00318136 [Accessed 2008 Mar 3]
A study to evaluate the efficacy of bevacizumab in combination with tarceva for advanced non-small cell lung cancer [Clinical-Trials.gov identifier: NCT00130728]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00130728 [Accessed 2008 Mar 3]
A study of avastin (bevacizumab) in combination with platinum-based chemotherapy in patients with advanced or recurrent squamous non-small cell lung cancer [ClinicalTrials.gov identifier: NCT00404703]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00404703 [Accessed 2008 Mar 3]
Bevacizumab, paclitaxel, carboplatin, and radiation therapy to the chest in treating patients with locally advanced non-small cell lung cancer [ClinicalTrials.gov identifier: NCT00369551]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00369551 [Accessed 2008 Mar 3]
Multimodality treatment for patients with resectable non-small cell lung cancer (NSCLC) —BEACON study: Bevacizumab and Chemotherapy for Operable NSCLC [ClinicalTrials.gov identifier: NCT00130780]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00130780 [Accessed 2008 Mar 3]
Sandler AB, Johnson DH, Brahmer J, et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC) [abstract no. 7068]. Proc Am Soc Clin Oncol 2006; 24: 381s
Acknowledgements
The authors have declared that they have received no funding to assist in the preparation of this review and have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Di Costanzo, F., Mazzoni, F., Mela, M.M. et al. Bevacizumab in Non-Small Cell Lung Cancer. Drugs 68, 737–746 (2008). https://doi.org/10.2165/00003495-200868060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200868060-00002